Vertex Pharmaceuticals Inc. Stock

Vertex Pharmaceuticals' (NASDAQ: VRTX) stock price is up, but its Casgevy sales partner, CRISPR Therapeutics (NASDAQ: CRSP), is the real buy for long-term investors.

Shares of Vertex, a biotech

Investors were snapping up shares of fintech stock Vertex (NASDAQ: VERX) on Thursday. That followed a rather glowing research update from an analyst at a prominent investment bank. With that in its

Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer and various genetic conditions is an obvious home run. CRISPR Therapeutics

Vertex Pharmaceuticals (NASDAQ: VRTX) hasn't made the headlines in recent times like companies involved in high-growth areas such as weight loss drugs or artificial intelligence (AI). But this

By all accounts its stock should be in the red today. CRISPR Therapeutics (NASDAQ: CRSP) only reported $864,000 in fourth-quarter revenue after Thursday's closing bell, leading to a loss of $1.37

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of a biotech success story. The company has developed strength in a specialty area and, thanks to that, has delivered a track record of

Vertex Pharmaceuticals (NASDAQ: VRTX) has underperformed the market over the past year, rising less than 2%. The biotech, known for its cystic fibrosis (CF) treatments, is scheduled to report

Vertex Pharmaceuticals (NASDAQ: VRTX) experienced several setbacks last year, sometimes following quarterly updates that weren't as strong as the market expected, or during which it also reported

After underperforming broader equities over the past few years, will the healthcare sector finally rebound and deliver above-average returns from here on out? That's hard to say. Whatever the case

Despite a few setbacks, Vertex Pharmaceuticals (NASDAQ: VRTX) performed pretty well last year, although it lagged the S&P 500. However, things could be very different in 2026. Thanks to several

On November 13, New York City-based Hyperion Capital Advisors disclosed a new position in Vertex (NASDAQ:VERX), acquiring 540,000 shares valued at approximately $13.39 million.

According to a filing

CRISPR Therapeutics (NASDAQ: CRSP) has had a volatile performance over the past five years. While its stock is up more than 40% this year, in three of the past five years it has fallen by more than

Healthcare stocks as a group have not performed on par with broader equities this year. However, that doesn't mean investors should avoid the sector altogether. Many healthcare companies appear to

On November 14, California-based Tensile Capital Management disclosed a buy of 160,559 shares of Vertex (NASDAQ:VERX) in the third quarter. Despite the expanded stake, the market value of the

Vertex Pharmaceuticals (NASDAQ: VRTX) has grown revenue and profit into the billions of dollars thanks to its expertise in the treatment of cystic fibrosis (CF). The company has developed a

Vertex Pharmaceuticals (NASDAQ: VRTX) has proven itself to be an excellent long-term investment, advancing 91% over the past five years. This is as the company has delivered steady growth in revenue

A lot can change in five years. Take Vertex Pharmaceuticals (NASDAQ: VRTX), for example. In late 2020, the big biotech company's approved products focused on one indication – cystic fibrosis (CF)

Vertex Pharmaceuticals (NASDAQ: VRTX) has not performed well for most of the year, and the company's latest quarterly update did nothing to turn things around. However, the market may be overlooking

Though it started the year strong, CRISPR Therapeutics (NASDAQ: CRSP) is experiencing a pullback. Over the past month, shares of the gene-editing specialist are down 23%. But there is plenty of

The stock of niche financial software company Vertex (NASDAQ: VERX) didn't get a very good start to the trading week at all. Its value fell by nearly 10% that day, due largely to a quarterly

I don't like the term "growth stock" all that much. Investors want their money to grow in some shape, form, or fashion with every stock they buy. However, I understand that textbook growth stocks

There are plenty of attractive stocks on the market. Some, though, have significantly underperformed their growth potential this year, making them attractive at their current levels.

This list

On Friday, Pennsylvania-based Conestoga Capital Advisors disclosed selling 855,435 shares of Vertex (NASDAQ:VERX), an estimated $24.8 million transaction based on average prices in the third

Equity markets are said to be forward looking. However, sometimes they fail to look far enough into the future by reacting too harshly to the challenges some companies face in the present. The good